In this preclinical study, we demonstrate that the MI ziftomenib, in combination with the XPO1 inhibitor selinexor, synergistically inhibited the growth of multiple <i>KMT2A-</i>r and <i>NPM1</i>-m AML cell lines (CI<1). This evidence concerns the gene XPO1 and acute myeloid leukemia.